CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 64 enrolled
Drug / intervention
BIA 9-1067 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01520727
NCT01520727Phase 1Completed
CompareCT.gov

A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects

Bial - Portela C S.A.·interventional·Posted Jan 30, 2012·Updated Jan 8, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 and Placebo for Parkinson Disease. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after single oral ascending doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesFrance
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 30, 2012
Enrollment StartOct 1, 2007
Primary CompletionDec 1, 2007
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.4 years ago

Interventions

BIA 9-1067drug

single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Placebodrug

single-dose